Who is sponsoring NCT02689999?

NCT02689999 is sponsored by Neutec Ar-Ge San ve Tic A.Ş.

What drugs are being tested in NCT02689999?

Interventions in NCT02689999: Dexrabeprazole 10 mg Enteric-Coated Tablets.

What condition does NCT02689999 study?

NCT02689999 studies Gastroesophageal Reflux Disease (GERD).

Is NCT02689999 still recruiting?

NCT02689999 is currently completed. Last updated 23 August 2017.

Last reviewed 2017-08-23 · How we verify

NCT02689999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Completed Phase 4 Last updated 23 August 2017

What this trial tests

Phase 4 trial testing Dexrabeprazole 10 mg Enteric-Coated Tablets in Gastroesophageal Reflux Disease (GERD) in 12 participants. Completed in 1 August 2017.

Timeline

1 February 2016

Primary endpoint
1 May 2017

1 August 2017

Quick facts

Lead sponsor	Neutec Ar-Ge San ve Tic A.Ş
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 February 2016
Primary completion	1 May 2017
Estimated completion	1 August 2017
Sites	3 locations across Turkey (Türkiye)

Drugs / interventions tested

Dexrabeprazole 10 mg Enteric-Coated Tablets — full drug profile →

Conditions studied

Gastroesophageal Reflux Disease (GERD) — all drugs for Gastroesophageal Reflux Disease (GERD) →

Sponsor

Neutec Ar-Ge San ve Tic A.Ş — full company profile →

Who can join

Adults 18 to 70, any sex, with Gastroesophageal Reflux Disease (GERD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

- The percent of pH < 4 duration of 24-hour intragastric acidity and intraesophageal acidity after seven-days treatment.
Time frame: One week
Multichannel intraluminal esophageal impedance pH-meter will be applied to cases in screening and second visit in order to evaluate the effect on 24-hour intragastric and intraesophageal acid values. 24-hour pH values of cases will be measured with pH-meter. Combined impedence pH catheter will be placed to 10 cm under and 5 cm upper of inferior esophageal sphincter of cases under local anesthesia.
- The area under curve (AUC) of pH < 4 duration of 24-hour intragastric acidity and intraesophageal acidity after seven-days treatment.
Time frame: One week
Multichannel intraluminal esophageal impedance pH-meter will be applied to cases in screening and second visit in order to evaluate the effect on 24-hour intragastric and intraesophageal acid values. 24-hour pH values of cases will be measured with pH-meter. Combined impedence pH catheter will be placed to 10 cm under and 5 cm upper of inferior esophageal sphincter of cases under local anesthesia.

Sponsor's own description

It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux Disease (GERD)

Currently open trials in the same condition.

NCT02616302 — A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux · Phase 2 · recruiting
NCT07174882 — Evaluation of the Clinical Course of NERD and Assessment of the Esophageal Mucosa Resistance · active not recruiting
NCT05870163 — Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment · recruiting
NCT06862037 — Development of Machine Learning Models to Predict Postoperative GERD Symptom Resolution After Laparoscopic Nissen Fundop · active not recruiting

Other Neutec Ar-Ge San ve Tic A.Ş trials

Trials by the same sponsor.

NCT05890638 — Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combinati · Phase 3 · unknown
NCT03177746 — The Safety of Dapoxetine/Tadalafil Combination Therapy · Phase 4 · unknown
NCT04457323 — S-Metoprolol XR 25-50 mg Tablets vs Metoprolol Zok 50-100 mg Tablets in Hypertension Patients. · Phase 4 · unknown
NCT04446637 — Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhale · Phase 3 · withdrawn
NCT03954613 — Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02689999 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neutec Ar-Ge San ve Tic A.Ş
Last refreshed: 23 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02689999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing